Anti-CTA monoclonal antibodies - Xenova Group

Alternative Names: HumaRAD_HN; HumaRAD_OV; KSB 309; KSB 310

Latest Information Update: 04 Aug 2004

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intracel Corporation
Developer Intracel Corporation; University of Nebraska Medical Center; Xenova Group
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

04 Aug 2004 Discontinued - Phase-I for Head and neck cancer in USA (unspecified route)
04 Aug 2004 Discontinued - Phase-I for Ovarian cancer in USA (unspecified route)
25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com